Acute Kidney Injury Clinical Trial
Official title:
Renin and Renal Biomarker Response to Angiotensin II Versus Controls in Septic Shock: An Open-Label Study
Verified date | August 2023 |
Source | University of Kentucky |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Septic shock continues to exert a large economic burden around the world. Several developments have occurred that lead to the current study. First, angiotensin II is the newest FDA approved vasopressor agent indicated for use in vasodilatory shock. Several subgroups from the approval trial have indicated that angiotensin II may confer a survival benefit in certain conditions, including those patients requiring continuous renal replacement therapy, those with altered angiotensin I: angiotensin II ratios, and most recently, those with elevated renin levels (which may serve as a surrogate for dysfunctional angiotensin 1: angiotensin II ratios). This open-label, sequential period pilot study will evaluate angiotensin II and biomarker response (renin) in the treatment of septic shock.
Status | Completed |
Enrollment | 30 |
Est. completion date | July 30, 2023 |
Est. primary completion date | July 24, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Medical ICU admission - Septic shock - Norepinephrine requirement = 0.15 mcg/kg/min for = 30 minutes (if cirrhosis, norepinephrine requirement = 0.1 mcg/kg/min for = 30 minutes) - Kidney Disease Improving Global Outcomes stage 1 or greater AKI Exclusion Criteria: - Prisoner - Pregnancy - Acute occlusive coronary syndrome requiring intervention or acute myocardial infarction of any degree - Purely cardiogenic shock (no distributive component) - Mesenteric ischemia - Acute ischemic stroke - Hemorrhagic shock - Active treatment of hepatorenal syndrome targeting a MAP = 65 mm Hg - Planned withdrawal of care within next 24 hours or no escalation of care - Patient enrolled in an interventional study - High likelihood of medical futility in using this drug: - 3 or more vasopressors required to sustain MAP - Sustained norepinephrine equivalents > 0.5 mcg/kg/min - COVID-19 positive, or high suspicion of COVID-19 |
Country | Name | City | State |
---|---|---|---|
United States | University of Kentucky HealthCare Chandler Medical Center | Lexington | Kentucky |
Lead Sponsor | Collaborator |
---|---|
Alexander Flannery |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Plasma Renin Levels | Plasma renin levels will be measured from blood collected at baseline, 24 hours, and at shock resolution. Additionally, a 3-hour measurement will be included in the angiotensin II arm. | Until shock resolution, up to 14 days (at baseline, 3 hours, 24 hours, and shock resolution, up to 14 days) | |
Secondary | Change in Renal Biomarkers | Cystatin C, NGAL will be measured from blood collected at baseline, 24 hours, and at shock resolution. | Until shock resolution, up to 14 days (at baseline, 24 hours, and shock resolution, up to 14 days) | |
Secondary | Time to discontinuation of catecholamines | Time from enrollment to discontinuation of catecholamines | Until shock resolution, up to 14 days | |
Secondary | ICU Length of Stay | Number of days in the intensive care unit (ICU). | From enrollment to ICU discharge, up to 28 days following enrollment | |
Secondary | In-hospital mortality | Assessment of all-cause mortality within hospital admission | Up to 3 months following enrollment | |
Secondary | Renal replacement therapy-free days | Days free of renal replacement therapy from enrollment up to day 28 | Within 28 days of enrollment | |
Secondary | Safety outcomes | Incidence of venous thromboembolism, arrhythmia, extremity hypoperfusion, delirium, new ischemic event, new infection | Up to 72 hours following shock resolution, no longer than 17 days from enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |